Rezolute to Participate in the BTIG Virtual Biotechnology Conference

(Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage ultra-rare disease company focused on treating refractory hypoglycemia caused by a congenital or any acquired form of hyperinsulinism (HI), ...
Healio

Neurological, pancreatic complications common in patients with congenital hyperinsulinism

Please provide your email address to receive an email when new articles are posted on . Neurological and pancreatic complications are common in patients with congenital hyperinsulinism. Existing ...
NorthernIrelandWorld on MSN

Miles of smiles as trust staff raise thousands for charity in Belfast marathon

Staff from across the South Eastern Trust came together recently to take part in the Belfast City Marathon, raising thousands of pounds for a range of charities close to their hearts.
Medical Xpress

Rapid genomic testing helps 1,100 families worldwide target treatment for rare childhood disease

An international partnership designed to improve equality in access to genomic medicine for a rare disease has now provided potentially life-saving genetic testing for over 1,100 families across the ...

Rezolute Prepares FDA Submission After sunRIZE Trial Review

An update from Rezolute ( (RZLT) ) is now available.
MarketWatch

Rezolute Says It Had Encouraging FDA Meeting on Congenital Hyperinsulinism Drug Despite Missed Endpoint

Rezolute said the Food and Drug Administration encouraged it to submit study reports and analysis datasets for its ersodetug drug to treat congenital hyperinsulinism, despite its Phase 3 study missing ...
TheHealthSite

Case Study: 1-month-old baby with rare Hyperinsulinism saved by world’s first robotic pancreatic surgery

When a life begins in the hospital corridor, most parents decide on cradles and toys to fill the house. But Baby Inaya's [name changed] parents were focused on a surgical schedule that would save ...
Nasdaq

Rezolute Provides Update on its Congenital Hyperinsulinism Program Following FDA Meeting

FDA encourages the Company to submit comprehensive data from sunRIZE and the ongoing open-label extension to inform next steps for the program REDWOOD CITY, Calif., March 24, 2026 (GLOBE NEWSWIRE) -- ...
STAT

The conundrum of false negative clinical studies in ultra-rare diseases

It is well known within the biopharma industry that clinical studies can produce any number of unexpected and possibly disappointing outcomes, including false negative results, or in statistical ...
조선일보

US FDA grants breakthrough status to Hanmi drug for congenital hyperinsulinism

Hanmi Pharmaceutical's bio novel drug under development for a rare disease has received breakthrough therapy designation from the U.S. Food and Drug Administration (FDA). Hanmi Pharmaceutical said on ...
Yahoo Finance

Rezolute Provides Insights from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism and Shares Findings from its Expanded Access Program in Tumor Hyperinsulinism

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...